Thank you, Mr. Chair.
I want to thank the witnesses for being here today.
I would say at this point that we've taken hundreds of mémoires from organizations that have presented to us. I think they're as diverse as the views we see here today. Quite honestly, this is meeting two of a three-meeting process. We're getting close, I believe, to the end of our process, where we need to have an idea of what we're going to recommend, and yet we have PMPRB changes going in place in just a few weeks. It's hard to synthesize a lot of the things we're seeing before us.
It was six months ago that we had our last meeting. We invited the PMPRB to be at this meeting to bounce some of these thoughts of them and for consultations. Unfortunately, they didn't want to be here today, which I find a bit awkward, as we're trying to find ways, to my mind, to help them come up with the best piece of rules and regulations in order to do that.
We talked a lot about pricing today, but we had the issue on the other side of the equation. We talked about the patient side.
Kelly Grover, thank you so much for being here on behalf of CF patients. I get a lot of folks from the patient groups talking to us. I know Tom will probably ask a few more questions on this if he gets the opportunity, but have you had an apology from PMPRB for what was truly their attack on patient groups? I find it difficult that we're attacking patient groups right now.